



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)



(51) International Patent Classification 4 : C07K 15/00, 3/28, C12P 21/00 C07H 19/06, A61K 37/00 C12N 15/00	A1	(11) International Publication Number: WO 89/01946 (43) International Publication Date: 9 March 1989 (09.03.89)
--	----	--

(21) International Application Number: PCT/US88/02819 (22) International Filing Date: 17 August 1988 (17.08.88) (31) Priority Application Number: 089,632 (32) Priority Date: 26 August 1987 (26.08.87) (33) Priority Country: US (60) Parent Application or Grant (63) Related by Continuation US Filed on 089,632 (CIP) 26 August 1987 (26.08.87) (71) Applicant (for all designated States except US): BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).	(72) Inventors; and (75) Inventors/Applicants (for US only) : DAYER, Jean-Michel [CH/CH]; 8, chemin Rieu, CH-1208 Geneva (CH). SECKINGER, Philippe, Lucien [FR/CH]; 4, rue Jacques Grosselin, CH-1227 Carouge (CH). MAZZEI, Gonzalo, Jose [CA/CH]; 11, rue Neckar, CH-1201 Geneva (CH). SHAW, Alan, Reed [US/CH]; 19, quai du Cheval Blanc, CH-1227 Geneva (CH). (74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 875 Third Avenue, New York, NY 10022-6250 (US). (81) Designated States: AT, AT (European patent), AU, BE (European patent), CH, CH (European patent), DE, DE (European patent), DK, FR (European patent), GB, GB (European patent), IT (European patent), JP, KR, LU (European patent), NL, NL (European patent), SE, SE (European patent), US. Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
--	--

(54) Title: BIOLOGICAL MATERIALS, PROCESSES FOR PRODUCING BIOLOGICAL MATERIALS AND FOR USING SUCH MATERIALS IN THERAPY
--

## (57) Abstract

This invention relates to interleukin 1 inhibitors (IL-1 INHs) that selectively inhibit interleukin 1 activity. The invention also relates to processes for purifying such IL-1 INHs from urine and for producing such IL-1 INHs by hosts transformed with recombinant DNA molecules comprising DNA sequences encoding the inhibitors, and to methods of treatment and compositions characterized by such IL-1 INHs. These methods and agents are useful in immunosuppressive and anti-inflammatory applications and therapies.



***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	FR France	ML Mali
AU Australia	GA Gabon	MR Mauritania
BB Barbados	GB United Kingdom	MW Malawi
BE Belgium	HU Hungary	NL Netherlands
BG Bulgaria	IT Italy	NO Norway
BJ Benin	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroon	LU Luxembourg	ID Chad
DE Germany, Federal Republic of	MC Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland		

-1-

BIOLOGICAL MATERIALS, PROCESSES FOR  
PRODUCING BIOLOGICAL MATERIALS AND  
FOR USING SUCH MATERIALS IN THERAPY

5

TECHNICAL FIELD OF INVENTION

This invention relates to interleukin 1 inhibitors (IL-1 INHs) that selectively inhibit interleukin 1 activity. The invention also relates to processes for purifying such IL-1 INHs from urine and for producing such IL-1 INHs by hosts transformed with recombinant DNA molecules comprising DNA sequences encoding the inhibitors, and to methods of treatment and compositions characterized by such IL-1 INHs. These methods and agents are useful in immunosuppressive and anti-inflammatory applications and therapies.

BACKGROUND ART

Interleukin 1 (IL-1) is a protein cytokine produced primarily by cells of the macrophage/monocyte lineage. There are two distinct IL-1 genes capable of encoding IL-1 polypeptides -- IL-1 $\alpha$  and IL-1 $\beta$  [P. Auron et al., "Nucleotide Sequence Of Human Monocyte Interleukin-1 Precursor cDNA", Proc. Natl. Acad. Sci., USA, 81, p. 7907 (1984); C. March et al., "Cloning, Sequences And Expression Of Two Distinct Human Interleukin 1 Complementary DNA's  $\alpha$  and  $\beta$ ," Nature, 315, p. 641 (1985)]. Studies of their respective biological activities using recombinant

-2-

IL-1 $\alpha$  and  $\beta$  have indicated thus far that both forms of IL-1 share multiple biological activities.

IL-1 has several distinct biological activities. One of these activities -- lymphocyte-activating factor (LAF) activity -- results in IL-1 being an immunological response mediator and as such, IL-1 stimulates the maturation, differentiation and growth of many cell types, such as immature T and B lymphocytes [P. Auron et al., Proc. Natl. Acad. Sci. USA, 81, supra]. Another of IL-1's activities -- mononuclear cell factor (MCF) activity -- results in IL-1 playing a central role in the regulation of diverse inflammatory responses [C. Dinarello, "An Update of Human Interleukin 1", J. Clin. Immun., 5, 10, p. 287 (1985)] and, as such, IL-1 stimulates several cells, e.g., fibroblasts and chondrocytes, to produce prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and collagenase, respectively. These responses are involved in the pathogenesis of such joint diseases as rheumatoid arthritis or diseases associated with the destruction of tissue [J. Dayer, "Cytokines and Other Mediators in Rheumatoid Arthritis", Springer Semin. Immunopath., 7, 15, p. 387 (1984)]. Further, IL-1 is known to induce the production of IL-2 [J. W. Lowenthal et al. "IL-1 20 Dependent Induction Of Both IL-2 Secretion and IL-2 Receptor Expression By Thymoma Cells", J. Imm., 137, 25 pp. 1226-1231 (1986)] which is involved in T-cell proliferation. Finally, IL-1 is also known to stimulate molecules on endothelial cells to trap white 30 blood cells [J. Oppenheim et al., "There is More Than One Interleukin 1", Immun. Today, 7, p. 45 35 (1986)].

It would therefore be of interest to identify and isolate an IL-1 inhibitor which suppresses antigen specific T-cell and B-cell proliferation and suppresses prostaglandin and collagenase synthesis by fibroblasts. Such a compound would be useful for

-3-

the treatment of disorders involving immune and inflammatory responses. Still further, it would be desirable to isolate an IL-1 inhibitor capable of suppressing IL-1 mediated IL-2 production. It is of 5 further interest to identify a compound that selectively inhibits the activities of IL-1 without con- commitantly inhibiting other proteins, e.g., tumor necrosis factors, such as TNF- $\alpha$ , that share several 10 biological properties of IL-1, i.e., PGE<sub>2</sub> and collagenase production by human dermal fibroblasts [J. Dayer et al., "Cachectin/Tumor Necrosis Factor Stimulates Collagenase and Prostaglandin E<sub>2</sub> Production by Human Synovial Cells and Dermal Fibroblasts", J. Exp. Med., 162, p. 2163 (1985)] or induction of 15 fibroblast proliferation [P. Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1  $\alpha$  And  $\beta$  But Not Tumor Necrosis Factor  $\alpha$ ", J. Immun., 139, p. 1541 (1987)].

20 At present, compounds reported as displaying inhibitory effects on IL-1, such as prostaglandins, act primarily as nonselective inhibitors. It has also been reported that urine of febrile patients contains a 20-30 kD selective inhibitor of IL-1 25 [Z. Liao et al. "Identification Of a Specific Inter- leukin 1 Inhibitor In The Urine Of Febrile Patients", J. Exp. Med., 159, p. 126 (1984)]. Liao does not sug- gest that this compound is other than in very crude form or that it inhibits the MCF activity of IL-1, 30 inhibits the binding of IL-1 to target cell receptors, or inhibits fibroblast proliferation in the presence of IL-1. A second compound reported to have IL-1 inhibitory effects [W. Arend et al., "Effects of Immune Complexes On Production By Human Monocytes of Interleukin or an Interleukin 1 Inhibitor", J. Immun., 134, p. 3868 (1985)] is produced by human monocytes cultured on adherent immune complexes. However, the 35

-4-

Arend report is ambiguous with respect to whether the compound inhibits both the LAF and MCF activity of IL-1 (see page 3874). In any event, the Arend article does not report that the compound is substantially pure or that it blocks IL-1 binding to target cell receptors or inhibits fibroblast proliferation in the presence of IL-1. A third compound reported to have IL-1 inhibitory effects [J-F. Balavoine et al., "Prostaglandin E<sub>2</sub> And Collagenase Production By Fibroblasts And Synovial Cells Is Regulated By Urine-derived Human Interleukin 1 And Inhibitor(s)", J. Clin. Invest. 78, p. 1120 (1986)] is suggested to be in very crude form and its mode of action is not described.

15

#### DISCLOSURE OF THE INVENTION

The present invention solves the problems referred to above by providing substantially pure IL-1 inhibitors ("IL-1 INHs") that selectively inhibit IL-1 LAF and IL-1 MCF activities, inhibit IL-1 mediated production of IL-2, inhibit IL-1 mediated fibroblast proliferation and bind to the IL-1 receptors on target cells, for use in immunosuppressive or in anti-inflammatory compositions, methods and therapies. The IL-1 INHs according to this invention do not inhibit TNF $\alpha$  mediated production of PGE<sub>2</sub> and collagenase in target cells. The IL-1 INHs of this invention are thus useful in a variety of compositions and methods for immunosuppressive and anti-inflammatory applications. The IL-1 INHs of our invention are characterized as being polypeptides having a molecular weight of approximately 25 kD on SDS/PAGE and an isoelectric point of 4.7 as determined by chromatofocussing.

One embodiment of a process of this invention for producing these IL-1 INHs is purification from natural sources. Such purification comprises

-5-

the steps of concentrating crude urine of febrile patients, precipitating crude IL-1 INH from the urine and fractionating the IL-1 INH from the other proteins of this precipitate by one or more of ion 5 exchange chromatography, hydrophobic chromatography, gel filtration and immunoabsorption.

A second and preferred embodiment of a process of this invention for producing these IL-1 INHs is the recombinant production of such inhibitors. 10 In such process, DNA sequences that code for the IL-1 INHs of this invention, recombinant DNA molecules characterized by those sequences and various unicellular hosts transformed with those DNA sequences and molecules are employed to produce the IL-1 INHs 15 of this invention (with or without an additional N-terminal methionine) or portions thereof by fermentation of the transformed hosts. It is to be understood that the IL-1 INH polypeptide according to this invention which displays IL-1 INH activity may 20 include various other amino acid substitutions, additions or deletions to the amino acid sequence of IL-1 INH.

Another object of this invention is to employ the IL-1 INHs of this invention to determine 25 the molecular structures and location of the active IL-1 INH sites and to use that information in designing fragments and peptides for use as IL-1 INHs in the immunosuppressive or anti-inflammatory compositions and methods of this invention.

30

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the activity profile of urinary IL-1 INH obtained from the QAE-Sepharose step.

35

Figure 2 depicts the activity profile of urinary IL-1 INH obtained from the DEAE-Sepharose step.

-7-

stimulates the proliferation of the CTLL cells which is measurable.

This invention relates to substantially pure IL-1 INHs. "Substantially pure" IL-1 INHs, as defined by this invention, are substantially free of major contaminants, especially apolipoprotein A1 and retinol binding protein, and migrate as a single band on SDS/PAGE.

The IL-1 INHs of this invention selectively inhibit IL-1 LAF and IL-1 MCF activities, inhibit IL-1 mediated IL-2 production by EL-4 cells, inhibit IL-1 mediated fibroblast proliferation and bind to the IL-1 receptors on target cells. Such selective inhibition is defined as having the ability to block IL-1 mediated activity while lacking the ability to block other compounds having some activities similar to IL-1, such as human recombinant TNF $\alpha$  (hrTNF $\alpha$ ) which is a mediator of PGE<sub>2</sub> and collagenase production. This specificity is an important factor for selectively blocking IL-1 without interfering with the necessary activity of other mediators of the immune system. We demonstrated this specificity of our IL-1 INHs by comparing the effect of the IL-1 INHs of this invention on the activity of IL-1 to hrTNF $\alpha$ , using the IL-1/MCF and fibroblast proliferation assays.

Most preferably, the IL-1 INHs of this invention have a molecular weight of about 25 kD on SDS-PAGE and an isoelectric point of 4.7 as determined by chromatofocussing.

The IL-1 INHs of this invention are capable of inhibiting an IL-1 mediated response in an LAF assay, a MCF assay, an EL-4/cytotoxic T-lymphocyte assay ("EL-4/CTLL") and a fibroblast proliferation assay. In the IL-1/LAF assay, the inhibition of IL-1 $\alpha$  or  $\beta$  induced T-cell proliferation is measured by detecting a reduction in level of incorporation

-8-

of [ $H^3$ ] thymidine in the presence of various dilutions of an IL-1 INH of this invention. In the IL-1/MCF assay the inhibition of IL-1 mediated  $PGE_2$  production is measured by a double antibody radioimmunoassay

5 using antiserum to  $PGE_2$  in the presence of various dilutions of IL-1 INH of this invention. The decrease of  $PGE_2$  into the medium detected by a radioimmunoassay indicates IL-1 INH activity. In the

10 EL-4/CTLL assay the inhibition of IL-1 mediated IL-2 production is measured in the presence of various dilutions of IL-1 INH of this invention. Inhibition is observed as a reduction in the level of uptake of [ $H^3$ ] thymidine ( $[H^3]$ -TdR) which is used as a measure of proliferation of CTLL cells. Proliferation only

15 occurs in the presence of IL-1 which induces IL-2 in a dose-dependent manner. In the fibroblast proliferation assay, the inhibition of  $[H^3]$ -TdR uptake by IL-1 induced fibroblasts is measured in the presence of various dilutions of an IL-1 INH of this invention.

20 As described above, the IL-1 INHs of this invention specifically bind to IL-1 receptors on target cells. This binding was demonstrated by using a series of IL-1 binding assays. First, we measured the effect of increasing concentrations of

25 IL-1 INH on the binding of labelled IL-1 to receptors on target cells. We observed that higher concentrations of IL-1 INH reduced the amount of bound labelled IL-1. Next, we added an excess of unlabelled IL-1 INH and observed the effect of that excess on the labelled IL-1 bound to a target cell. This assay demonstrated that excess IL-1 INH successfully competed with and replaced the labelled IL-1 bound to the surface of the target cells. We further added an excess of retinol binding protein and observed

30 that this did not prevent the binding of the IL-1 INH to the target cells. This assay demonstrated

35

-9-

that our IL-1 INHs compete specifically with IL-1 to bind to the IL-1 receptors on target cells.

This invention also relates to a purification process for isolating an IL-1 INH of this invention from natural sources, e.g., highly febrile patients or AIDS patients suffering from opportunistic infections. This process comprises several steps. In general outline these steps are (1) concentrating urine; (2) precipitating crude IL-1 INH from the concentrated urine and fractionating the IL-1 INH from the other proteins of this precipitate by at least one of ion exchange chromatography, hydrophobic chromatography, gel filtration and immunoabsorption.

In the preferred embodiment of this process, we first concentrate crude urine from febrile patients using standard procedures, e.g., ultrafiltration. We next precipitated a crude fraction containing the IL-1 INH from the concentrated urine pool using ammonium sulfate. After removing the ammonium sulfate by dialysis, we separate the fractions containing the IL-1 INH activity from other proteins using ion exchange chromatography. Specifically, in our most preferred embodiment we employ two anion exchangers -- a diethyl-(2-hydroxypropyl) aminoethyl-Sepharose column ((QAE)-Sepharose column) and a diethylaminoethyl-Sepharose column ((DEAE)-Sepharose column) -- independently or in combination, the DEAE Sepharose column preferably following the QAE Sepharose column. For monitoring the activity of the various fractions, we employed LAF and receptor binding assays. In this embodiment of our invention the IL-1 INH active fractions are next fractionated based on molecular weight using gel filtration, most preferably on a AcA54 gel, again selecting the active fractions as above. The selected fractions are characterized by a molecular weight of about 25kD and by representing at least 90% of the protein con-

-10-

tent. Principle contaminants are apolipoprotein AI and retinol binding protein. Although these contaminants may be removed in various ways, we prefer to employ monoclonal or polyclonal antibodies raised 5 against apolipoprotein and retinol binding protein by the method of immunoabsorption.

The above IL-1 INH active fractions are further purified by hydrophobic chromatography on a phenyl-Sepharose column which fractionates proteins 10 according to their hydrophobicity. Apolipoprotein AI and retinol binding protein, for example, are more hydrophobic than proteins of this invention and hence will be retained on the column.

Using the above-described preferred process, 15 the specific activity of the IL-1 INH of this invention, i.e., the amount of IL-1 INH required to produce half-maximal inhibition, increased after each purification step. See Figure 9. We used an IL-1 receptor binding assay, an LAF assay, an EL-4/CTLL assay and 20 a MCF assay to measure this specific activity. However, several other assays could have as well been used.

The IL-1 INH purified in the above process, or preferred process, may be used directly in the 25 immunosuppressive and anti-inflammatory compositions and methods of this invention. However, we prefer to use such purified protein as a source of amino acid sequence data to permit our design of DNA probes for use in isolating and selecting a DNA sequence 30 coding for an IL-1 INH of this invention. Such DNA sequences, recombinant DNA molecules including them, and unicellular hosts transformed with them may then be employed to produce large amounts of the IL-1 INHs 35 of this invention, substantially free from other human proteins, for use in the compositions and therapies of this invention.

-11-

More specifically, we determine the amino acid sequences of various portions and fragments of our purified IL-1 INH. We then use those sequences and the DNA sequences deduced as coding for them to 5 design a series of DNA probes potentially useful in screening various DNA libraries for DNA sequences coding for the IL-1 INHs of this invention. Such libraries include chromosomal gene banks and DNA or cDNA libraries prepared from tissue or cell lines 10 that are demonstrated to produce the IL-1 INHs of this invention; such cell lines include monocytic cell lines well known in the art.

As a means for preparing cDNA and finally cloning and expressing IL-1 INH polypeptides, poly 15 A<sup>+</sup> mRNA is isolated from an IL-1 INH producing cell source, such as stimulated macrophages, using conventional procedures, for example, those described by Land et al., "5-Terminal Sequences Of Eukaryotic mRNA Can Be Cloned With High Efficiency", Nucleic 20 Acids Research, 9, pp. 2251-66 (1981); Okayoma and Berg, "High Efficiency Cloning Of Full-Length cDNA, Mol. and Cell. Biol., 2, pp. 161-70 (1982); and Maniatis et al. in "Molecular Cloning" (ed. Cold 25 Spring Harbor Laboratory, Cold Spring Harbor, New York), pp. 229-46 (1982). Next, a cDNA library from the poly A<sup>+</sup> mRNA isolated above is constructed using conventional procedures, for example, those described by Wickens et al. "Synthesis Of Double-Stranded DNA Complementary To Lysosyme, Ovomucoid 30 And Ovalbumin mRNAs", J. Biol. Chem., 253, pp. 2483-95 (1978); Maniatis et al. in "Molecular Cloning" (ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York), pp. 229-46 (1982); and V. Gubler et al. "A Simple And Very Efficient Method 35 For Generating cDNA Libraries", Gene, 25, pp. 263-69 (1983).

-12-

There are several approaches to screening a library of clones for one containing a particular recombinant DNA molecule, i.e., one containing an IL-1 INH insert. For example, on the basis of a 5 partial amino acid sequence of our purified IL-1 INH, DNA probes that comprise a series of synthetic DNA fragments that code for selected portions of the IL-1 INHs of this invention can be constructed. Techniques for determining amino acid sequences are 10 well known in the art. Having determined the amino acid sequences of various regions of IL-1 INH, pools of degenerate IL-1 INH probes can be chemically synthesized using conventional phosphoamide DNA synthesis techniques for use in screening a variety of 15 DNA libraries to select related DNA sequences by hybridization. The DNA probes are then 5' end-labelled with <sup>32</sup>P using <sup>32</sup>P-ATP and T4 polynucleotide kinase, substantially as described by A. M. Maxam and W. Gilbert, "A New Method For Sequencing DNA", 20 Proc. Natl. Acad. Sci. USA, 74, pp. 560-64 (1977). These DNA probes are then used to screen cDNA or genomic libraries, e.g., cDNA libraries derived from monocytic leukemic cell lines U937, THP-I and HL60 25 for DNA sequences that encode IL-1 INHs of this invention using conventional methods. These selected sequences may then be manipulated for the expression of IL-1 INHs in prokaryotic and eukaryotic hosts transformed with them by techniques well known in the art. They are also useful as screening probes 30 to select other related DNA sequences that code for mammalian IL-1 INHs.

The DNA sequences and DNA molecules of the present invention may be expressed using a wide variety of host/vector combinations. For example, 35 useful vectors may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences, such as various known derivatives of SV40 and known bacterial

-13-

plasmids, e.g., plasmids from E.coli including colE1, pCR1, pBR322, pMB9 and RP4; phage DNAs, e.g., the numerous derivatives of phage, e.g., NM 989, and other DNA phages, e.g., M13 and other Filamentous 5 single-stranded DNA phages; vectors useful in yeasts, such as the 2 $\mu$  plasmid; vectors useful in eukaryotic cells, such as vectors useful in animal cells, such as those containing SV-40 adenovirus and retrovirus derived DNA sequences and and vectors derived from 10 combinations of plasmids and phage DNAs, such as plasmids which have been modified to employ phage DNA or other derivatives thereof.

Such expression vectors are also characterized by at least one expression control sequence 15 that is operatively linked to the IL-1 INH DNA sequence inserted in the vector in order to control and to regulate the expression of that cloned DNA sequence. Examples of useful expression control sequences are the lac system, the trp system, the 20 tac system, the trc system, major operator and promoter regions of phage  $\lambda$ , the control region of fd coat protein, the glycolytic promoters of yeast, e.g., the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, e.g., Pho5, 25 the promoters of the yeast  $\alpha$ -mating factors, and promoters derived from polyoma, adenovirus, retrovirus, and simian virus, e.g., the early and late promoters or SV40, and other sequences known to control the 30 expression of genes of prokaryotic or eukaryotic cells and their viruses or combinations thereof.

Among such useful expression vectors are vectors that enable the expression of the cloned IL-1 INH DNA sequences in eukaryotic hosts, such as animal and human cells [e.g., P. J. Southern and 35 P. Berg, J. Mol. Appl. Genet., 1, pp. 327-41 (1982); S. Subramani et al., Mol. Cell. Biol., 1, pp. 854-64 (1981); R. J. Kaufmann and P. A. Sharp, "Amplifica-

-14-

tion And Expression Of Sequences Cotransfected with A Modular Dihydrofolate Reductase Complementary DNA Gene", J. Mol. Biol., 159, pp. 601-21 (1982); R. J. Kaufmann and P. A. Sharp, Mol. Cell. Biol., 159, 5 pp. 601-64 (1982) S. I. Scahill et al., "Expression And Characterization Of The Product Of A Human Immune Interferon DNA Gene In Chinese Hamster Ovary Cells", Proc. Natl. Acad. Sci. U.S.A., 80, pp. 10 4654-59 (1983); G. Urlaub and L. A. Chasin, Proc. Natl. Acad. Sci. USA, 77, pp. 4216-20 (1980)].

Furthermore, within each specific expression vector, various sites may be selected for insertion of the IL-1 INH DNA sequences of this invention. These sites are usually designated by the restriction 15 endonuclease which cuts them. They are well recognized by those of skill in the art. It is to be understood that an expression vector useful in this invention need not have a restriction endonuclease site for insertion of the chosen DNA fragment. 20 Instead, the vector could be joined to the fragment by alternative means. The expression vector, and in particular the site chosen therein for insertion of a selected DNA fragment and its operative linking therein to an expression control sequence, is determined by a variety of factors, e.g., number of sites 25 susceptible to a particular restriction enzyme, size of the protein to be expressed, susceptibility of the desired protein to proteolytic degradation by host cell enzymes, contamination or binding of the 30 protein to be expressed by host cell proteins difficult to remove during purification; expression characteristics, such as the location of start and stop codons relative to the vector sequences, and other factors recognized by those of skill in the 35 art. The choice of a vector and an insertion site for a DNA sequence is determined by a balance of

-15-

these factors, not all selections being equally effective for a given case.

Useful expression hosts include well known eukaryotic and prokaryotic hosts, such as strains of 5 E.coli, such as E.coli SG-936, E.coli HB 101, E.coli W3110, E.coli X1776, E.coli X2282, E.coli DHI, and E.coli MRC1, Pseudomonas, Bacillus, such as Bacillus subtilis, Streptomyces, yeasts and other fungi, animal, such as COS cells and CHO cells, and human 10 cells and plant cells in tissue culture.

Of course, not all host/expression vector combinations function with equal efficiency in expressing the DNA sequences of this invention or in producing the IL-1 INH-like polypeptides of this 15 invention. However, a particular selection of a host/expression vector combination may be made by those of skill in the art after due consideration of the principles set forth herein without departing from the scope of this invention. For example, the 20 selection should be based on a balancing of a number of factors. These include, for example, compatibility of the host and vector, toxicity of the proteins encoded by the DNA sequence to the host, ease of recovery of the desired protein, expression characteristics of the DNA sequences and the expression control 25 sequences operatively linked to them, biosafety, costs and the folding, form or any other necessary post-expression modifications of the desired protein.

The IL-1 INHs produced by fermentation of 30 the prokaryotic and eukaryotic hosts transformed with the DNA sequences of this invention, can then be employed in the immunosuppressive and anti-inflammatory compositions and methods of this invention.

35 The IL-1 INHs of this invention can also be analyzed to determine their active sites for producing fragments or peptides, including synthetic peptides, having the activity of IL-1 INHs. Among

-16-

the known techniques for determining such active sites are x-ray crystallography, nuclear magnetic resonance, circular dichroism, UV spectroscopy and site specific mutagenesis. Accordingly, these fragments or peptides are also part of this invention and may be employed in immunosuppressive or anti-inflammatory targets and methods of it.

Administration of the IL-1 INH polypeptides of this invention, or peptides derived or synthesized from them or using their amino acid sequences, or their salts or pharmaceutically acceptable derivatives thereof, may be via any of the conventionally accepted modes of administration of agents which exhibit immunosuppressive or anti-inflammatory activity. These include oral, parenteral, subcutaneous, intravenous, intralesional or topical administration. Local, intralesional or intravenous injection are preferred.

The compositions used in these therapies may also be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, suppositories, injectable and infusible solutions. The preferred form depends on the intended mode of administration and therapeutic application. The compositions also will preferably include conventional pharmaceutically acceptable carriers and may include other medicinal agents, carriers, adjuvants, excipients, etc., e.g., human serum albumin or plasma preparations. Preferably, the compositions of the invention are in the form of a unit dose and will usually be administered one or more times a day.

In order that our invention herein described may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and should

-17-

not be construed as limiting this invention in any way to the specific embodiments recited therein.

EXAMPLES

Example 1: Purification of IL-1 INH

5        a) Concentration of Protein From Human Urine

At 4°C, 100 liters of pooled urine from highly febrile patients (>38.5°C) devoid of urinary infections were concentrated on an Amicon ultrafiltration hollow fiber apparatus to two liters. The 10 resulting solution had a specific activity of 12 U/mg of protein as determined by the IL-1 receptor assay described in Example 2, 166 U/mg of protein as determined by the LAF assay described in Example 3, 32 U/mg of protein as determined by the EL-4/CTLL 15 assay described in Example 4, and 125 U/mg of protein as determined by the MCF assay described in Example 5. A "U" or Unit is defined as the amount of IL-1 INH (μg) which produces half maximal inhibition in each bioassay. See Figure 9.

20        b) Precipitation of Protein From Human Urine

We first saturated the concentrated urine pool with solid ammonium sulphate, by adding the ammonium sulphate slowly with constant stirring at 25 4°C until we reached an ammonium sulphate saturation of 40%. We next removed the precipitate from the solution by centrifugation in an Sorvall RC-5B (E. I. Du Pont, New Town, Conn.) using a fixed angle GSA rotor at 10'000 rpm for 1 hour. We next discarded 30 the pellet and adjusted the supernatant to 80% saturation ammonium sulphate and centrifuged at 10'000 rpm for 1 hour. We then resuspended the resultant pellet in 20 mM sodium phosphate (pH 7.2) with 150 mM NaCl (650 ml). We then dialyzed the solution for 24 hrs. 35 against 45 liters (twice) containing 10 mM Tris HCl

-18-

(pH8), 2 mM EDTA and 5 mM benzamidine HCl to remove the ammonium sulphate.

c) Ion-exchange Chromatography

We next separated the IL-1 INH activity in  
5 our combined fraction from other proteins by making  
use of IL-1 INH's strong binding affinity to two  
different anion exchangers. Each anion exchanger  
was employed independently or in combination, the  
DEAE Sepharose column preferably following the QAE  
10 Sepharose column.

1) Diethyl-(2-hydroxypropyl)aminoethyl  
(QAE) Sepharose Column

While many anion exchange chromatographic systems are well known to those skilled in the art,  
15 we chose to use first a QAE-Sepharose column, 5 cm in diameter X45 cm (Pharmacia Fine Chemicals, Piscataway, New Jersey). After loading the above dialysed solution we washed the column until nonbound proteins were eluted (optical density at 280 nm).  
20 We eluted the bound proteins with four column volumes of a salt gradient of 0 to 0.8 M NaCl dissolved in the equilibration buffer. The column-flow was 120 ml/h. We monitored the activity of the various fractions using the LAF and receptor binding assays  
25 (infra). See Figure 1. The fractions displaying the biological activity of IL-1 INH eluted around 150 mM NaCl. The combined active fractions had a specific activity of 33 U/mg of protein as determined by the IL-1 receptor binding assay as described in  
30 Example 2, 63 U/mg of protein as determined by the LAF assay as described in Example 3, 27 U/mg of protein as determined by the EL-4/CTLL assay as described in Example 4, and 200 U/mg of protein as determined by the MCF assay as described in Example 5. See  
35 Figure 9.

-19-

2) Diethylaminoethyl (DEAE) Sepharose Column

We dialyzed the active pool against 10 mM Tris HCl (pH 7) loaded on a DEAE-Sepharose fast flow column, 2.5 cm X 30 cm (Pharmacia Fine Chemicals, Piscataway, New Jersey). The column loaded with the active pool was washed with equilibrium buffer (10 mM Tris HCl, pH 7) until optical density (at 280 nm) was around 0. We then eluted the bound protein with a gradient from 0 to 0.2 M NaCl dissolved in the equilibrium buffer. The gradient was 10 times the volume of the column. The column-flow was 78 ml/h. Again, we monitored the activity of the various fractions as above. This elution afforded elution of the fractions containing IL-1 INH activity at the end of the 90 mM NaCl wash step. Figure 2 shows the activity profile of urinary IL-1 inhibitor on the DEAE-Sepharose, in which the inhibitory activity was followed on (A) IL-1/LAF assay and (B) IL-1/receptor binding assay (infra).

We next concentrated the active pool to 6 ml by an Amicon ultrafiltration apparatus using a YM-10 membrane. The resulting solution had a specific activity of 50 U/mg of protein as determined by the IL-1 receptor binding assay (infra), 125 U/mg of protein as determined by the LAF assay (infra), 40 U/mg of protein as determined by the EL-4/CTLL assay (infra), and 500 U/mg of protein as determined by the MCF assay (infra). See Figure 9.

It should, of course, be understood that other anion exchange columns could also have been chosen without departing from the scope of this invention.

d) Ultrogel AcA54

We next fractionated twice the concentrate prepared as described above, according to molecular

-20-

weight, using gel filtration. While a number of suitable gel filtration systems are well known to those skilled in the art, we chose to use an AcA54 gel (LKB, Sweden) with a fractionation range from 6000-  
5 70,000 daltons. Again, we monitored the activity of the fractions as above. See Figure 3. The resulting pool of the active fractions had a specific activity of 1666 U/mg of protein as determined by an IL-1 receptor binding assay (infra), 526 U/mg of protein  
10 as determined by the LAF assay (infra), 333 U/mg of protein as determined by EL-4/CTLL assay (infra), 1110 U/mg of protein as determined by the MCF assay (infra) (see Figure 9) and a molecular weight of approximately 25 kD. Again, it should be understood  
15 that other filtration systems could also have been used.

Figure 4 illustrates the dose-response of the various urinary IL-1 INH pools on the (A) IL-1/LAF assay and (B) IL-1/receptor binding assays  
20 described below. After each purification step, i.e., concentrated urine; QAE-Sepharose; DEAE-Sepharose; and AcA54 (twice), the concentration ( $\mu$ g/ml) of IL-1 INH required to achieve inhibition decreased indicating a purer protein.

25 e) Negative-Immunoabsorption

We analyzed the active pool from the gel filtration by amino acid sequencing, using the conventional method of automated Edman degradation, and observed that the two major contaminants representing  
30 at least 90% of the protein content were apolipoprotein AI and retinol binding protein. Although various methods are available to remove these proteins, we chose immunoabsorption and hydrophobic chromatography.

35 Hence, we next separated out the major contaminants from the IL-1 INH AcA54 active pool by

-21-

immunoabsorption. Monoclonal and polyclonal anti-bodies against retinol binding protein and apolipoprotein AI were generated using standard methods of immunization. We then partially purified 5 the immunoglobulin Gs (IgGs) by precipitation with 40% ammonium sulphate saturation. The IgG pellet was resuspended in 0.2 M sodium phosphate and dialyzed against the same buffer. We next coupled the IgG pool to vinylsulfone-activated agarose as described 10 by the manufacturers (KEM-EN-TEC, Biotechnology Corp., Denmark). After equilibrating the immunoabsorbent, with phosphate buffered saline we absorbed the contaminants from the IL-1 INH pool by passing the pool several times over the immunoabsorbant until 15 any retinol binding protein and apolipoprotein AI were completely absorbed as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The resulting solution had a specific activity of 3334 U/mg of protein as determined by 20 the IL-1 receptor binding assay (infra) 2500 U/mg of protein as determined by the LAF assay (infra) 1250 U/mg of protein as determined by the EL-4/CTLL assay (infra) 2160 U/mg of protein as determined by the MCF assay (infra) (see Figure 9) and displayed a 25 single peak on SDS/PAGE.

f) Phenyl-Sepharose

The immunoabsorbed IL-1 inhibitor pool was adjusted to 1M NaCl by adding one volume of 2M NaCl dissolved in 10 mM Tris HCl pH 7 and loaded to Phenyl-Sepharose (0.5 x 5 cm, this resin was obtained from 30 Pharmacia Fine Chemicals Sweden). The resin was previously equilibrated with 10 mM Tris HCl, pH 7, containing 0.2 M NaCl (equilibration buffer). After the loading the column was washed with 3 column 35 volumes of equilibration to elute all the non-bound proteins and the bound proteins were eluted with a

-22-

gradient from 0.2 M NaCl to 0 M dissolved in 10 mM Tris HCl, pH 7. The total gradient was 50 times the column volume. The column-flow was 30 ml/h. The IL-1 inhibitor activity was eluted around 0.160 M NaCl given a protein of 25 Kda M.W. with a PI of 4.7. The resulting solution had a specific activity of 38461 U/mg of protein as determined by the IL-1 receptor binding assay as described in Example 2, 2,500 U/mg of protein as determined by the LAF assay as described in Example 3, 35,020 U/mg of protein as determined by the EL-4/CTLL assay as described in Example 4, 30,303 U/mg of protein as determined by the MCF assay as described in Example 5 (see Figure 9) and displayed a single peak on SDS/page.

15 Example 2: Receptor Binding Ability of IL-1 INH

To determine the binding characteristics of our IL-1 INH to the IL-1 receptor on EL-4-6.1 target cells, we first tested to see if IL-1 INH interfered with the binding of [<sup>125</sup>I]-IL-1 to the target cells. We labeled IL-1 with <sup>125</sup>I by the Chloramine T method [Lowenthal et al., "Binding and Internalization of Interleukin-1 by T Cells," J. Exp. Med., 164, p. 1060] and coincubated it with an excess of unlabeled IL-1 INH, followed by washing on an oil gradient. Using a gamma counter, we next measured the retained material with the cells and found that increasing the concentration of IL-1 INH reduced the amount of [<sup>125</sup>I]-IL-1 bound to the surface of the target cells.

We further tested to see if IL-1 INH interfered with the binding of [<sup>125</sup>I]-IL-1 INH to the target cells, whether binding of [<sup>125</sup>I]-IL-1 INH could be competed by unlabeled IL-1 or whether binding of [<sup>125</sup>I]-IL-1 INH to the target cells could be competed with retinol binding protein or apolipoprotein

-23-

AI. With [<sup>125</sup>I], we labeled IL-1 INH by the method of Bolton and Hunter [Bolton and Hunter "The labelling Of Proteins To High specific Radioactivities By conjugation to a <sup>125</sup>I-Containing Acylating Agent,"

5      Biochem. J., 133, p. 529 (1973)]. Incubation of the material with EL-4-6.1 target cells followed by washing on an oil gradient, and analyzing on SDS PAGE showed that a species of approximately 25 kD binds to the EL-4 cells. We observed the coincubation of 10      the [<sup>125</sup>I]-IL-1 INH with an excess of unlabeled IL-1 INH prevented the binding of the labeled 25 kD species. We also coincubated the [<sup>125</sup>I]-IL-1-INH with 50 nanograms of unlabeled IL-1 $\beta$  and found this prevented the binding of the labeled 25 kD species. 15      We also coincubated the [<sup>125</sup>I]-IL-1 INH with 1  $\mu$ g of immunopurified retinol binding protein and with 1  $\mu$ g of recombinant apolipoprotein AI and found that this did not prevent the binding of the labeled 25 kD species. Thus the 25 kD species present in the 20      labeled IL-1 INH preparation binds to the surface of intact EL-4-6.1 cells, and this binding is competed by unlabeled inhibitor and by IL-1, but not by retinol binding protein or apolipoprotein AI.

Example 3: IL-1/LAF Assay

25      We demonstrated the inhibitory activity of IL-1 INH in a IL-1/LAF assay, as measured by thymocyte (T-cell) proliferation in the C<sub>3</sub>H/HeJ mouse [J. M. Dayer et al., "Human Recombinant IL-1 Stimulates Collagenase And Prostaglandin E2 Production By Human Synovial Cells", J. Clin Invest., 77, p. 645 (1986)]. We costimulated the thymocyte cells for 72 hours with PHA (1  $\mu$ g/ml) in the presence of either hrIL-1 $\alpha$  [P. Wingfield et al., "Purification and Characterization Of Human Interleukin-1 Expressed 30      In E.coli." Eur. J. Biochem., 165, p. 537 (1987)] or IL-1 $\beta$  [P. Wingfield et al., "Purification And 35

-24-

Characterization Of Human Interleukin-1 $\beta$  Expressed In Recombinant E.coli", Eur. J. Biochem., 160, p. 491 (1986)] at different final concentrations ranging from 20 pg/ml to 2,000 pg/ml of hrIL-1 as shown in 5 Figure 5. We obtained complete inhibition of the costimulated hIL-1 $\alpha$  or hIL-1 $\beta$  thymocyte proliferation when we added the IL-1 INH fractions from example 1(e) to the cells. Inhibitory activity was monitored at three dilutions of IL-1 INH:1/20, 1/40 10 and 1/80.

Since addition of IL-1 INH to PHA-stimulated cells, in the absence of hrIL-1 did not affect [ $H^3$ ]-TdR incorporation, we determined that inhibition was not due to a cytotoxic or non-specific 15 effect but to inhibition of IL-1 biological activity.

Example 4: EL-4/CTLL Assay

We determined IL-1 INH's inhibitory activity by observing whether IL-1 $\alpha$ 's or IL-1 $\beta$ 's ability to induce production of IL-2 in EL-4 cells could be 20 inhibited [see, e.g., A.J.H. Gearing et al., "A Simple Sensitive Bioassay For IL-1 Which is Unresponsive to 10<sup>3</sup> U/ml Of IL-2", J. Immun. Met., 99, p. 7 (1987)]. This is measured by co-culturing a subclone of EL-4 cells unable to take-up thymidine from 25 surrounding medium with CTLL-2 cells and observing whether the CTLL-2 cells proliferate.

EL-4.6.1 cl0 cells and CTLL-2 cells were cultured together at a concentration of 10<sup>4</sup> cells of each type per microtiter well (96 well plate) in 30 the presence of IL-1 $\alpha$  or IL-1 $\beta$  at about 1 picogram/ml, together with IL-1 INH from Example 1(e). We added 1 microCurie of [ $H^3$ ]-TdR after 18 hrs. of co-culture and incubated for an additional 6 hours at 37°C in a humidified atmosphere. Cells were harvested on a 35 MASH cell harvester onto glass fiber strips, dried and prepared with scintillation cocktail for counting

-25-

in a beta counter. We obtained complete inhibition of [ $\text{H}^3$ ]-TdR incorporation at IL-1 INH dilutions of 1/20, 1/40 and 1/80.

Example 5: IL-1/MCF Assay

5 We further demonstrated the inhibitory activity of IL-1 INH in a IL-1/MCF assay as measured on fibroblasts obtained from human infant foreskin [J. Dayer et al., "Participation Of Monocyte-Macrophage And Lymphocyte In The Production Of A 10 Factor That Stimulates Collagenase And Prostaglandin Release By Rheumatoid Synovial Cells," J. Clin. Invest., 64, p. 1386 (1979); J. Dayer et al. "Induction Of Human Interleukin-1 mRNA Measured By Collagenase And Prostaglandin E2-Stimulating Activity In 15 Rheumatoid Synovial Cells," Eur. J. Immunol., 14, p. 898 (1984)]. We stimulated the fibroblasts with hrIL-1 $\alpha$  or hrIL-1 $\beta$  at the same concentrations as in the IL-1/LAF assay, and monitored the inhibitory activity at the same final dilutions of IL-1 INH as 20 in the IL-1/LAF assay. After we cultured the cells for 72 hours, we measured the prostaglandin E<sub>2</sub> production in fibroblast supernatants by a double antibody radioimmunoassay [J. Dayer (1979), supra] using an antiserum to prostaglandin E<sub>2</sub>. As shown in Figure 6, 25 we observed a dose response of prostaglandin E<sub>2</sub> production up to concentrations of 100 pg/ml by either hrIL-1 $\alpha$  or hrIL-1 $\beta$ . We were able to inhibit this biological activity by adding the IL-1 INH fractions from Example 1(e). We determined that IL-1 INH was again effective against hrIL-1 $\alpha$  and hrIL-1 $\beta$ .

30 We then performed the above assay substituting hrTNF $\alpha$  [A. Marmenout et al., "Molecular Cloning and Expression of TNF And Comparison With Mouse TNF", Eur. J. Biochem., 152, pp. 515-22 (1985)] for hrIL-1 to determine the specificity of IL-1 INH, since TNF $\alpha$  35 is also a mediator of prostaglandin E<sub>2</sub> and collage-

-26-

nase production. As shown in Figure 7, hrTNF -induced prostaglandin E<sub>2</sub> production was not significantly affected by addition of our IL-1 INH, illustrating the specificity of our IL-1 INH.

5      **Example 6: Fibroblast Proliferation Assay**

We further assayed IL-1's biological activity in the presence of the IL-1 INH from Example 1(e) using a fibroblast proliferation assay, measured by [<sup>3</sup>H]-TdR incorporation. After culturing 10 human foreskin fibroblasts in Eagle's MEM supplemented with 10 mM HEPES, penicillin 100 U/ml, streptomycin 100 ug/ml, 1% glutamine, 1% non-essential amino acids and 2% FCS, we seeded the cells in 96-well plates (2000 cells/well) and cultured for 15 24 hours in a 5% CO<sub>2</sub> incubator at 37°C. After removing the medium we stimulated the fibroblast cells by adding either hrIL-1 $\alpha$  or hrIL-1 $\beta$  and added IL-1 INH at the same dilutions as the above assays. We waited 48 hours and then pulsed the cells with 20 [<sup>3</sup>H]-TdR for a further 16 hours. Medium was removed from the cells which were then washed with PBS and trypsinized at 37°C for 15 additional minutes. With a cell harvester (Skatron, Lier, Norway) we collected 25 the cells onto glass filters (Skatron, Inc., Sterling, Virginia, U.S.A.) washed with water, air dried and determined the cpm incorporation using a scintillation counter. As shown in Figure 8, fibroblast proliferation was dose-dependent for hrIL-1 $\alpha$  and hrIL-1 $\beta$ . We obtained maximal [<sup>3</sup>H]-TdR incorporation with 30 250 pg/ml of hrIL-1 $\alpha$  or  $\beta$ . Addition of the AcA54 inhibitory fraction resulted also in a complete decrease of hrIL-1-induced proliferation. We also achieved complete reversibility of inhibition by increasing IL-1 concentrations or by diluting the 35 IL-1 INH.

-27-

We also determined the specificity of this inhibition by stimulating the fibroblasts with hrTNF $\alpha$ , which induces fibroblast proliferation in a dose-dependent fashion up to concentrations of 250 pg/ml.

5 Our addition of the AcA54 inhibitory fraction did not result in the inhibition of hrTNF $\alpha$  bioactivity. This confirms the specificity of the IL-1 INH.

**Example 7: Determination Of The Isoelectric Point**

We used the pool of protein eluted from  
10 Example 1(e) to load on a PBE 94 chromatofocusing (Pharmacia Fine Chemical, Sweden) column (2.5 X 10 cm) previously equilibrated with 25 mM imidazole (pH 7.5). We added a polybuffer 74 HCl, pH 4, which afforded elution of bound proteins, depending on their iso-  
15 electric points. We determined that the pI of the IL-1 INH is 4.7.

While we have hereinbefore described a number of embodiments of this invention, it is apparent that our basic constructions can be altered  
20 to provide other embodiments which utilize the processes and compositions of this invention.

Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than the specific embodiments  
25 which we have presented by way of example.

-28-

CLAIMS

WE CLAIM:

1. A substantially pure IL-1 INH, the IL-1 INH being characterized by an inhibitory activity to the LAF activity of IL-1, to the MCF activity of IL-1, to IL-1 mediated fibroblast proliferation, and non-inhibitory activity to the TNF $\alpha$  mediated production of PGE<sub>2</sub> and collagenase.  
5
2. The IL-1 INH according to claim 1 wherein IL-1 INH is further characterized by an inhibitory activity to IL-1-mediated production of IL-2.  
10
3. The IL-1 INH according to claim 1, wherein the IL-1 INH specifically binds to IL-1 receptors on target cells.  
15
4. The IL-1 INH according to any one of claims 1 to 3, wherein the IL-1 INH has a molecular weight of about 25,000 daltons on SDS PAGE.  
20
5. The IL-1 INH according to claim 4, wherein the IL-1 INH has an isoelectric point of 4.7 by chromatofocussing.  
25
6. The IL-1 INH according to any one of claims 1-5 wherein the IL-1 INH is substantially free from other proteins.  
7. The IL-1 INH according to claim 6 wherein the other proteins is selected from the group consisting of apolipoprotein A1 and retinol binding protein.  
8. The IL-1 INH according to claim 1

-29-

wherein the IL-1 INH has a specific activity of at least  $1.2 \times 10^3$  U/mg in an EL-4/CTLL assay.

9. The IL-1 INH according to claim 1, wherein the IL-1 INH has a specific activity of at least  $3.8 \times 10^4$  U/mg in an IL-1 receptor binding assay.

10. The IL-1 INH according to claim 1, wherein the IL-1 INH has a specific activity of at least  $6.2 \times 10^4$  U/mg in an IL-1/LAF assay.

10 11 The IL-1 INH according to claim 1, wherein the IL-1 INH has a specific activity of at least  $3.5 \times 10^4$  U/mg in an EL-4/CTLL assay.

15 12. The IL-1 INH according to claim 1, wherein the IL-1 INH has a specific activity of at least  $3.0 \times 10^4$  U/mg in an IL-1/MCF assay.

20 13. A method of purifying an IL-1 INH according to any one of claims 1 to 12, comprising the steps of a) concentrating urine from febrile patients; b) precipitating crude IL-1 INH from the concentrated urine; and c) fractionating the IL-1 INH from other contaminants by at least one of ion exchange chromatography, hydrophobic chromatography, gel filtration and immunoabsorption.

25 14. The method according to claim 13, wherein the crude IL-1 INH is precipitated from the concentrated urine using ammonium sulfate.

30 15. A method of purifying an IL-1 INH according to any one of claims 1 to 12 comprising fractionating the IL-1 INH from other contaminants by at least one of ion exchange chromatography,

-30-

hydrophobic chromatography, gel filtration and immunoabsorption.

16. The method according to claim 13 or 15, wherein the ion exchange chromatography is carried out on QAE or DEAE Sepharose columns, independently or in combination.

17. The method according to claim 13 wherein the gel filtration is carried out on an AcA54 gel.

10 18. The method according to claim 13 wherein the immunoabsorption is carried out employing monoclonal or polyclonal antibodies to retinol binding protein and apolipoprotein Al.

15 19. A method of producing a recombinant DNA molecule characterized by a DNA sequence coding for an IL-1 INH according to any of claims 1 to 12 comprising the steps of

20 (a) determining the amino acid sequence of a purified IL-1 INH;

(b) making a pool of oligonucleotide probes based on the amino acid sequence of step (a);

(c) screening a DNA or cDNA library;

(d) selecting clones that hybridize

25 under conventional conditions to the probes; and

(e) analyzing the selected clones by sequencing or expression to determine whether they contain a DNA sequence coding for the IL-1 INH.

30

-31-

20. A recombinant DNA molecule comprising a DNA sequence which codes on expression for an IL-1 INH according to any one of claims 1 to 12.

5 21. The recombinant DNA molecule according to claim 20, further comprising an expression control sequence, said expression control sequence being operatively linked to the DNA sequence which codes for the IL-1 INH in the recombinant DNA molecule.

10 22. The recombinant DNA molecule according to claim 21, wherein the expression control sequence is selected from the group consisting of the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage, the control region of fd coat protein, the early and 15 late promoters of SV40, promoters derived from polyoma, adenovirus and simian virus, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, the promoter of the yeast  $\alpha$ -mating factors and combination thereof.

20 23. A process for producing an IL-1 INH according to any one of claims 1 to 12 comprising the step of culturing a unicellular host transformed with a recombinant DNA molecule according to claims 21 or 22.

25 24. A pharmaceutical composition comprising a therapeutically effective amount of an IL-1 INH according to any one of claims 1 to 12 or produced by the methods of any of claims 13 to 18 in a pharmaceutically acceptable vehicle.


30 25. A method for treating immune diseases and inflammation comprising the step of treating in

-32-

a pharmaceutically acceptable manner a mammal with a composition according to claim 24.


119

FIG. 1




219

FIG. 2





3 / 9

FIG. 3



4 / 9

FIG. 4



- ▲ = ACA54, 2<sup>nd</sup> FILTRATION FRACTION
- △ = ACA54, 1<sup>st</sup> FILTRATION FRACTION
- × = DEAE - SEPHAROSE COLUMN FRACTION
- = QAE - SEPHAROSE COLUMN FRACTION
- = URINARY FRACTION

5 / 9

## IL 1 INH ACTIVITY MEASURED IN THE IL 1/LAF ASSAY FIG. 5

FINAL CONCENTRATION OF hrIL-1 (pg/ml) TO PHA- STIMULATED THYMOCYTES	FORM OF hrIL-1 ADDED TO THE THYMOCYTES	FINAL DILUTION OF AC54 INHIBITORY FRACTION <sup>a</sup>		
		NONE	1/20	1/40
20	α	3.5 ± 0.4	1.0 ± 0.1	1.1 ± 0.1
	β	5.7 ± 0.4	1.0 ± 0.1	1.0 ± 0.2
40	α	8.6 ± 3.0	1.0 ± 0.1	0.9 ± 0.1
	β	8.2 ± 2.0	1.0 ± 0.1	1.2 ± 0.2
100	α	14.6 ± 1.0	1.0 ± 0.1	1.4 ± 0.1
	β	15.4 ± 2.2	1.2 ± 0.1	1.6 ± 0.1
2000	α	24.7 ± 3.5	10.2 ± 1.5	16.0 ± 3.1
	β	20.1 ± 2.6	20.1 ± 2.6	12.1 ± 4.0

<sup>a</sup> BUFFER (NONE) OR AC54 (18-25kD) INHIBITORY FRACTIONS (SEE FIG.1) WERE INCUBATED AT VARIOUS DILUTIONS IN THE PRESENCE OR ABSENCE OF DIFFERENT CONCENTRATIONS OF EITHER hrIL1α OR hrIL1β.

<sup>b</sup> [<sup>3</sup>H]-TdR INCORPORATION IN THYMOCYTES IN THE PRESENCE OF PHA (IL 1/LAF) WAS MEASURED. VALUES REPRESENT MEANS ± SEM (N=3).

6 / 9

FIG. 6 IL 1 INH ACTIVITY MEASURED IN THE IL 1/MCF ASSAY


FINAL CONCENTRATION OF nrIL-1 (pg/ml) ON HUMAN FIBROBLASTS	FORM OF nrIL-1 ADDED TO THE FIBROBLASTS	FINAL DILUTION OF ACAS 54		INHIBITORY FRACTION <sup>a</sup> 1/80
		None	1/20	
0	-	0.5 ± 0.1	8 ± 3.6	8 ± 2.9 7 ± 2.0
20	α	20 ± 4.6	8 ± 3.5	6 ± 2.6 10 ± 4.8
	β	17 ± 3.1	12 ± 3.1	11 ± 2.0 12 ± 5.0
40	α	41 ± 9.6	13 ± 4.2	10 ± 0.9 12 ± 5.1
	β	28 ± 8.6	13 ± 5.8	13 ± 3.4 6 ± 2.2
100	α	62 ± 11.1	8 ± 3.8	15 ± 8.2 16 ± 2.1
	β	55 ± 5.2	15 ± 6.4	21 ± 6.0 26 ± 5.1
2000	α	46 ± 3.9	49 ± 7.4	71 ± 10.2 87 ± 11.7
	β	64 ± 13	47 ± 7.0	57 ± 39.0 113 ± 16.2

<sup>a</sup> BUFFER (None) OR ACAS 54 (10 - 25 KD) INHIBITORY FRACTIONS (SEE FIG. 1) WERE INCUBATED AT VARIOUS DILUTIONS IN THE PRESENCE OR ABSENCE OF DIFFERENT CONCENTRATIONS OF EITHER nrIL-1α OR nrIL-1β.

♦ PGE2 PRODUCTION BY CULTURED HUMAN DERMAL FIBROBLASTS WAS MEASURED AFTER 3 DAYS OF CULTURE. VALUES REPRESENT MEANS ± SEM (N=3)

7 / 9

FIG. 7

 $[^3\text{H}]$  TDR INCORPORATION IN FIBROBLASTS (cpm ·  $10^{-2}$ )

8 / 9

## IL 1 INH ACTIVITY MEASURED IN THE IL 1/FIBROBLAST PROLIFERATION ASSAY FIG. 8

FINAL CONCENTRATION OF hIL 1 (pg/ml) ON HUMAN DERMAL FIBROBLASTS	FORM OF hIL 1 ADDED TO THE FIBROBLASTS	FINAL DILUTION OF AC54 INHIBITORY FRACTION <sup>a</sup>			[ <sup>3</sup> H]-TdR INCORPORATION IN HUMAN DERMAL FIBROBLASTS (cpm/0.1 <sup>b</sup> )
		NONE	1/20	1/40	
0		1.3 ± 0.4	1.2 ± 0.3	1.1 ± 0.3	1.4 ± 0.4
20	α	2.1 ± 0.4	1.1 ± 0.3	1.0 ± 0.3	1.4
	β	2.7 ± 0.2	1.6 ± 0.1	1.3 ± 0.3	1.6
40	α	2.5 ± 0.3	0.9 ± 0.1	1.1 ± 0.4	1.1
	β	3.9 ± 0.2	1.3 ± 0.1	1.6 ± 0.1	2.4
100	α	3.1 ± 0.6	1.0 ± 0.3	1.4 ± 0.2	2.4
	β	4.0 ± 0.4	1.6 ± 0.3	2.0 ± 0.2	2.7
250	α	4.0 ± 0.6	1.6 ± 0.1	2.1 ± 0.5	3.3
	β	4.3 ± 0.8	1.9 ± 0.2	2.4 ± 0.4	2.6
2,000	α	3.8 ± 0.5	2.8 ± 0.7	3.0 ± 0.3	4.0
	β	4.1 ± 0.6	2.8 ± 0.4	3.4 ± 0.6	4.8

<sup>a</sup> BUFFER (NONE) OR AC54 (18-25 kD) INHIBITORY FRACTIONS (SEE FIG. 1) WERE INCUBATED AT VARIOUS DILUTIONS IN THE PRESENCE OR ABSENCE OF DIFFERENT CONCENTRATIONS OF EITHER hIL 1 OR hIL 1b. <sup>b</sup> [<sup>3</sup>H]-TdR INCORPORATION IN DERMAL FIBROBLASTS (IL 1 PROLIFERATION) WAS MEASURED. VALUES REPRESENT MEANS ± SEM (N=3).

FIG. 9

PURIFICATION OF THE IL-1 INHIBITOR

STEP	BIOASSAYS				*UNITS/mg	
	PROTEIN ACTIVITY	SPECIFIC ACTIVITY	TOTAL ACTIVITY	YIELD		SPECIFIC ACTIVITY
<u>IL-1 RECEPTOR BINDING</u>						
1 CONCENTRATION URINE	15190	12	192	100	1	166
2 QAE-SEPHAROSE	3350	33	112	58	3	63
3 DEAE-SEPHAROSE	480	50	24	13	4	125
4 ACA 54 (I)	48	454	22	12	37	40
5 ACA 54 (II)	9.3	1666	16	8	138	500
6 NEGATIVE-IMMUNO- ABSORPTION	0.9	3334	3	1.6	277	250
7 PHENYL-SEPHAROSE	0.053	38461	2	1	3205	62500
						35020
						30303
<u>IL-1/EL-4/CTL MCF</u>						
						125
						200
						500
						540
						1110
						333
						2160

\*UNIT (D<sub>50</sub>) IS DEFINED AS THE AMOUNT OF IL-1 INHIBITOR (μg) PRODUCING A HALF-MAXIMAL INHIBITION ON THE BIOASSAYS, i.e. IL-1 RECEPTOR BINDING, IL-1/LAF, IL-1/EL-4-CTL CO-CULTURE AND IL-1/MCF BIOASSAYS.

9 / 9

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/02819

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC  
 Int. CL: C07K 15/00, 3/28; C12P 21/00; C07H, 19/06; A61k 37/00; C12N 15/00  
 U.S. CL 530/350, 351, 412, 413, 416, 417; 435/68, 172.3; 536/26, 27; 935/2, 6;

## II. FIELDS SEARCHED

Minimum Documentation Searched ?

Classification System	Classification Symbols
U.S.	530/350, 351, 412, 413, 416, 417, 820; 435/68, 172.3; 935/2, 6, 60, 65; 536/26, 27; 514/2, 21, 885

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched \*

Search on CAS and Dialog Files CA, Biosis 350, 351, 155 For:  
IL-1-inhibitor, DNA or RNA, recombinant, process of purification;  
treatment of the immune system or inflammation.

## III. DOCUMENTS CONSIDERED TO BE RELEVANT \*

Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X Y	Journal Clin. Invest., vol. 78, Issued October 1986 (Balavoine), "Prostaglandin E <sub>2</sub> and Collagenase Production by Fibroblast and Synovial cells is regulated by Urine derived Human Interleukin 1 and Inhibitors", pages 1120-24, see pages 1120-21.	1-15, 17 16, 18 24-25
X Y	Einstein Q Journal Biol. Med., vol. 5, Issued 1987, (Rosenstreich), "Interleukins and Interleukin Inhibitors A Review", (pages 10-18), Biosis Abstract No. 87: 208860.	1-4 5-18, 24-25
X Y	Journal Exp. Med., Vol. 159, Issued January 1984, (Liao), "Identification of A Specific Interleukin 1 Inhibitor in the Urine of Febrile Patients", pages 126-136, see pages 126-27, 131.	1-4, 6-7 8-18, 24-25

\* Special categories of cited documents: <sup>10</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

22 November 1988

Date of Mailing of this International Search Report

09 JAN 1989

International Searching Authority

ISA/US

Signature of Authorized Officer

*Garnette D. Draper*

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category*	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X Y	Journal Immunol., Vol. 134, Issued June 1985, (Arend), "Effects of Immune Complexes on Production By Human Monocytes of Interleukin 1 or An Interleukin 1 Inhibitor", pages 3868-75, see pages 3868, 3873.	<u>1-4, 6-7</u> 8-18, 24-25
X Y	Chemical Abstract, Vol. 106, Issued 1987, "Increased production of an interleukin-1 (IL-1) inhibitor with fibroblast stimulating Activity by mononuclear cells from patients with scleroderma", Abstract No. 65645r, (Sandborg), Clin. Exp. Immunol. 1986, 66(2), pages 312-19.	<u>1-3</u> 5-18, 24-25
X Y	Journal Immunol., Vol. 137, Issued October 1986, (Kemp), "Inhibition of Interleukin 1 Activity By A Factor in Submandibular Glands of Rats, "pages 2245-51, see pages 2245, 2250.	<u>1-7</u> 8-18, 24-25
X Y	Proc. Natl. Acad. Sci., Vol. 83, Issued December 1986, (Brown), "Uromodulin, an Immunosuppressive Protein Derived from Pregnancy Urine, is an Inhibitor of Interleukin 1", pages 9119-23, see pages 9119.	<u>1-3, 6-7</u> 8-18, 24-25

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V.  OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1.  Claim numbers \_\_\_\_\_, because they relate to subject matter<sup>1,2</sup> not required to be searched by this Authority, namely:

2.  Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out<sup>1,2</sup>, specifically:

3.  Claim numbers \_\_\_\_\_, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI.  OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

Group I, claims 1-12, 24-25 to IL-1 INH, composition and use thereof; 530/351 and 514/2. Group II, claims 13-18 to a method of purifying IL-1 INH, 530/412. Group III, claims 19-23 to a method of preparing DNA, to DNA and a method of using the DNA to produce IL-1 INH, 435/172.3, 536/26

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4.  As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

The additional search fees were accompanied by applicant's protest.  
 No protest accompanied the payment of additional search fees.

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category*	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No <sup>18</sup>
X Y	Journal Exp. Med., Vol. 163, Issued March 1986, (Rorberts), "Interleukin 1 and Interleukin 1 Inhibitor Production By Human Macrophages Exposed To Influenza Virus or Respiratory Syncytial Virus", pages 511-19, see pages 514.	1-3 6-18, 24-25
X Y	Journal Immunol. vol. 136, Issued May 1986, (Tiku), "Normal Human Neutrophils are a source of a specific Interleukin 1 Inhibitor, "pages 3686-92, see page 3686.	1-3 6-18 24-25
X Y	Chemical Abstract, vol. 107, Issued 1987, "Isolation and purification of IL-5 an interleukin 1 inhibitor produced by human gingival epithelial cells," Abstract No. 37792p, (Walsh), Clin. Exp. Immunol., 1987, 68(2), pages 366-74.	1-3 6-18, 24-25
X	Journal Immunol., Vol. 138, Issued March 1987, "UV-Irradiated Epidermal Cells Produce A Specific Inhibitor of Interleukin 1 Activity", (Schwarz), see pages 1457-63. See page 1457, 1461-62.	1-3, 24-25
X	Chemical Abstract, Vol. 107, Issued 1987, "Human Urine-derived Inhibitors of Interleukin 1", Abstract No. 215786z, (Rosenstreich), Rev. Infect. Dis. 1987, a (Suppl. 5), S594-98.	1, 24-25
Y	Bio Techniques, Issued Nov/Dec 1983 "Designing an Optimal Chromatographic Purification Scheme for Proteins", (Sofer), pages 198-203.	13-18

Detailed Reasons For Holding Lack of Unity of Invention:

The invention as defined by Group I (claims 1-12, 24-25) is drawn to IL-1 INH, a pharmaceutical composition thereto, and use thereof; classified in classes 530 and 514, subclasses 351 and 2 respectively. Group II (Claims 13-18) is drawn to a method of purifying IL-1 INH; classified in class 530 subclass 412. Group III (claims 19-23) is drawn to a method of preparing DNA to IL-1 INH, to the DNA, and to the use of the DNA to prepare the protein; classified in classes 435, 935 and 536, subclasses 1723, and 26 respectively.

PCT Rule 13.2 permits claims to a(one) product, a method of making the product, and a method of using the product. The invention of Groups I+III encompass various products, methods of preparing the products, and different methods of use. The methods of Groups II and III represent different methods of preparing the IL-1 INH. There is no provision in Rule 13.2 for claims covering multiple products, preparations of each, and methods of use of each products.